Celadon Pharmaceuticals Plc

LSE CEL.L

Celadon Pharmaceuticals Plc Debt to Equity Ratio for the year ending December 31, 2023: 1.49

Celadon Pharmaceuticals Plc Debt to Equity Ratio is 1.49 for the year ending December 31, 2023, a 147.49% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Celadon Pharmaceuticals Plc Debt to Equity Ratio for the year ending December 31, 2022 was 0.60, a -66.60% change year over year.
Celadon Pharmaceuticals Plc Debt to Equity Ratio for the year ending December 31, 2021 was 1.81, a -93.88% change year over year.
Celadon Pharmaceuticals Plc Debt to Equity Ratio for the year ending December 31, 2020 was 29.52.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

LSE: CEL.L

Celadon Pharmaceuticals Plc

CEO	Mr. James Gareth Short
IPO Date	March 31, 2022
Location	United Kingdom
Headquarters	32-33 Cowcross Street
Employees	27
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Tobacco

Description

Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years